CTIBiotech
Develops advanced human tissues and cell models using 3D bioprinting (bioextrusion) to create humanized alternatives to animal testing for drug, cosmetic, and medical research.
- CEO / Founder
- Nico Forraz
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- €1M
- Latest Round
- Grant
- Key Investors
- Sanofi, Bpifrance, French Government (France 2030)
Technology & Products
Key Products
3D bioprinted tissue models (skin, oncology, inner ear organoids) for drug, cosmetic, and medical research.
Technological Advantage
Proprietary cell amplification technology (1M to 1B keratinocytes) and bioextrusion of multi-layered humanized tissues; ISO 9001:2015 certified processes.
Differentiation
Value Proposition
Reduces R&D costs and ethical concerns by providing humanized 3D bioprinted tissue models (skin, oncology) that serve as high-fidelity alternatives to animal testing for pharma and cosmetics.
How They Differentiate
Differentiates by integrating sensory nervous and immune systems into 3D bioprinted skin models, providing higher biological complexity than standard structural models.
Market & Competition
Target Customers
Pharmaceutical/biotech companies, cosmetics firms, medical device developers, hospitals, and universities.
Industry Verticals
Cosmetics, Oncology, Immuno-oncology, Regenerative Medicine, Drug/Vaccine/Device testing.
Competitors
Poietis, TissUse, Organovo
Growth & Milestones
Growth Metrics
Cell amplification capability: produces 1 billion keratinocytes from 1 million.
Major Milestones
Created world's first artificial liver-like tissue (pre-2009); ISO 9001:2015 certified; IFSCC 2025 'Cosmetic Scientist' award; French 'PERL' recognition.
Notable Customers
BASF, Chanel, Sanofi, Eurofins, Transgene, French Army (LPP), Institut Pasteur, Clarins